Head-to-head evidence
Anrikefon (HSK21542) vs Difelikefalin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Kappa-opioid receptor (agonist, peripherally restricted) · full Chronic Kidney Disease pipeline
Anrikefon (HSK21542)
Developed by Haisco Pharmaceutical Group
NCT05135390 · Phase 3 · completed
This was a randomized, double-blinded, placebo-controlled trial with 545 patients and a validated itch-severity response endpoint. Anrikefon significantly outperformed placebo, with 37% of patients reaching a large itch improvement versus 15% on placebo (p<0.001).
Next expected readout: December 2027 · NCT07380113 (registry estimate)
Difelikefalin · Korsuva
Marketed by Vifor Pharma and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07526324 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anrikefon (HSK21542)'s landscape · Difelikefalin's landscape